News - Transgene, Analgesia

Filter

Current filters:

TransgeneAnalgesia

Popular Filters

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec

27-03-2014

France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

Study: Half of veterans prescribed medical opioids continue to use them chronically

Study: Half of veterans prescribed medical opioids continue to use them chronically

07-03-2014

A study of nearly 1 million veterans who receive opioids to treat painful conditions found that more…

AnalgesiaHealthcarePharmaceuticalResearchUSA

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

Sanofi and Transgene launch construction phase of joint bioproduction platform

Sanofi and Transgene launch construction phase of joint bioproduction platform

29-01-2014

French drug major Sanofi and biotech firm Transgene have launched the construction phase of the manufacturing…

BiotechnologyFranceOncologyProductionSanofiTransgene

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

27-11-2013

Privately-held South Korean firm SillaJen says it has executed a definitive merger agreement to acquire…

BiotechnologyJennerexMergers & AcquisitionsOncologyPexa-VecSillaJenTransgene

Altus signs $4 million agreement with Zogenix to license Zohydro ER

04-11-2013

Altus Pharmaceuticals has entered into an agreement with Zogenix to develop abuse deterrent formulations…

AnalgesiaLicensingNorth AmericaPharmaceuticalZogenixZohydro

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests

30-10-2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

Zogenix shares leap after FDA approval for Zohydro ER

Zogenix shares leap after FDA approval for Zohydro ER

28-10-2013

Shares of Zogenix rocketed on Friday after the US Food and Drug Administration approved Zohydro ER extended-release…

AnalgesiaNorth AmericaPharmaceuticalRegulationZogenixZohydro

FDA calls for reclassification of codeine combo medications to stricter schedules

FDA calls for reclassification of codeine combo medications to stricter schedules

25-10-2013

The US Food and Drug Administration has indicated that it wants to see the classification of codeine-containing…

AnalgesiaHydrocodone Bitartrate and AcetaminophenNorth AmericaPharmaceuticalRegulation

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Iroko’s pain relief drug effective at low doses

Iroko’s pain relief drug effective at low doses

22-10-2013

Iroko Pharmaceuticals has announced that the US Food and Drug Administration has approved Zorvolex capsules…

AnalgesiaIrokoNorth AmericaPharmaceuticalRegulationZorvolex

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Transgene's Pexa-Vec fails in mid-stage liver cancer study

04-09-2013

French biotech firm Transgene (Euronext Paris: TNG) has revealed that TRAVERSE, a randomized Phase IIb…

BiotechnologyOncologyPexa-VecResearchTransgene

Transgene out-licenses skin cancer candidate TG1042 to Ascend Pharma

04-07-2013

French biotech firm Transgene SA (Euronext Paris: TNG) has granted Ascend Biopharmaceuticals, an emerging…

Ascend PharmaASN-002BiotechnologyLicensingOncologyTG1042Transgene

Transgene to seek partner for HCV vaccine TG4040 on strong Ph II results

09-11-2011

French biotech firm Transgene (Euronext Paris: FR0005175080) has revealed interim data showing a substantial…

BiotechnologyLicensingOncologyPharmaceuticalResearchTransgeneVaccines

Transgene, ChronTech Pharma and Inovio to collaborate on hep C vaccine

21-04-2011

France’s Transgene (Euronext Paris: FR0005175080) has signed a collaboration agreement with Sweden’s…

Anti-viralsChronTech PharmaInovio PharmaceuticalsPharmaceuticalResearchTransgeneVaccines

Company Spotlight

Fibrotech

Fibrotech

Back to top